Summary & Overview
HCPCS J7327: Monovisc (Hyaluronan) Intra-Articular Injection
HCPCS Level II code J7327 denotes a single dose of Monovisc (hyaluronan or derivative) for intra-articular injection, a viscosupplementation treatment commonly used for symptomatic management of joint pain. Nationally, this code is important because it records a specific injectable biologic product distinct from other intra-articular therapies, affecting billing, utilization tracking, and payer coverage pathways for osteoarthritis and related joint conditions. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J7327 represents clinically and operationally, payer coverage considerations across major national insurers, and benchmarks relevant to claims and reimbursement categories. The publication summarizes typical sites of service, common billing modifiers (list provided separately), and areas where policy updates or prior authorization requirements commonly affect utilization. It also outlines where data are available and flags items omitted when input data were not provided. The intent is to inform billing staff, revenue cycle managers, and policy analysts about the code’s clinical context, payer landscape, and operational implications for documenting and reporting intra-articular Monovisc injections.
Billing Code Overview
HCPCS Level II code J7327 represents hyaluronan or derivative, monovisc, for intra-articular injection, per dose. The service is the administration of a single dose of a hyaluronan derivative formulated for intra-articular use, typically intended for viscosupplementation in joints.
-
Service type: Intra-articular hyaluronan injection
-
Typical site of service: Outpatient clinic, physician office, or ambulatory surgical center for joint injection procedures
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with symptomatic knee osteoarthritis presents to an orthopedic clinic after conservative management (physical therapy, NSAIDs, and activity modification) provided inadequate pain relief. The clinician confirms focal tibiofemoral joint pain on exam with radiographic evidence of moderate osteoarthritic change. The decision is made to perform an intra-articular injection of a single-dose hyaluronan derivative, administered as J7327 (Monovisc) to provide viscosupplementation and symptomatic relief.
The clinical workflow includes: pre-procedure informed consent and medication reconciliation; verification of indication and absence of infection; optional imaging guidance (ultrasound or fluoroscopy) for accurate intra-articular needle placement; aseptic skin preparation and local anesthetic if indicated; administration of the J7327 dose into the joint; post-injection observation for immediate adverse reaction; documentation of the product lot number, dose, site (e.g., LT/RT when applicable), and patient response; and scheduling follow-up to assess pain and function. Billing will include the HCPCS Level II code J7327 and may include anatomic site modifier LT or RT when required by the payer.
Coding Specifications
| Modifier |
|---|